As Reckitt Benckiser shares slip, I’m looking to buy

Short-term challenges could be creating a long-term opportunity for investors with Reckitt Benckiser plc (LON: RB).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Let’s get the bad news out of the way first. Reckitt Benckiser (LSE: RB), the FTSE 100 fast-moving consumer goods company, just lowered its revenue and profit outlook for 2019.

Naturally, the shares are weak today, but I’m cheering the falling share price because I’d like to buy the stock on better terms for the long haul.

A focus on execution

The third-quarter results report reveals the Health division delivered a 0.3% decline in like-for-like revenue during Q3. Year to date, the decline in sales has clocked up 0.6%, and Health represents about 60% of total turnover. In the Hygiene Home division, responsible for the remaining 40%, like-for-like sales fared better, rising 4.5% in Q3, and 3.3% year to date.

Those figures don’t look too bad, but chief executive Laxman Narasimhan declared in the report that the performance was “disappointing.” He reckons the weakness in the Health business was because of “more cautious retailer seasonal purchasing patterns” in the US, and “challenging” market conditions in China for the firm’s infant nutrition offering.

But he also said the company’s performance reflects “an extended period of significant change and disruption” in the company. It seems the firm needs to pull its socks up and get the basics right because Narasimham is prioritising improvements in execution and operational performance while pausing everything else.

Despite these potentially short-term challenges, the business and the sector are attractive to me. Narasimham reckons the firm’s products address high-growth categories. And it’s hard to argue against the potential for the company’s “high-growth” and “market-leading” brands such as Dettol, Durex, Gaviscon, Harpic, Cillit Bang and Vanish.

Clear and addressable challenges

The issues are “clear and addressable,” according to the top executive. And that makes me optimistic we could be seeing short-term problems knocking the share price, which could throw up an opportunity to buy into the long-term story on better terms.

With the share price at 5,758p, the forward-looking earnings multiple for 2020 sits just over 16, and the anticipated dividend yield is around 3.1%. That’s not a bargain valuation but the business scores well against quality indicators.

For example, the operating margin runs just below 25% and the return on capital at about 11%. And over the past few years, revenue, earnings, cash inflow and the dividend have all been rising steadily.

Indeed, the fast-moving consumer goods sector is known for its defensive qualities, meaning that demand for the branded goods supplied by firms such as Reckitt Benckiser can remain resilient even during general economic downturns.  That’s why I believe this company would make a decent dividend-led investment with the aim of holding the shares for the long term.

And if the share price shows more weakness, the temptation for me to buy will become too great to ignore. Right now, I reckon the shares are more attractive than a cyclical, such as Whitbread, for example.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young female stock-picker in a cafe
Investing Articles

Q1 results boost the Bunzl share price: investors should consider the stock for stability

As the Bunzl share price edges higher, our writer considers whether this so-called boring FTSE 100 stock looks like a…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

The top 5 investment trusts to buy in a resurgent UK stock market?

These were the five most popular investment trusts at Hargreaves Lansdown in April. And they're not the ones I'd have…

Read more »

woman sitting in wheelchair at the table and looking at computer monitor while talking on mobile phone and drinking coffee at home
Investing Articles

The smartest dividend stocks to consider buying with £500 right now

In the past few years, the UK stock market’s been a great place to find dividend stocks paying top yields.…

Read more »

2024 year number handwritten on a sandy beach at sunrise
Investing Articles

Why this FTSE 100 company is the first I’m buying for my 24/25 Stocks and Shares ISA

As a new Stocks and Shares ISA year gets underway, it’s time to start searching for my next additions. Barclays…

Read more »

Investing Articles

How much passive income would I make from 945 National Grid shares?

National Grid shares pay a healthy dividend that, over time, can produce a sizeable passive income if the dividends are…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

These 7 UK shares turned £50k into £550k

Investing in individual UK shares can be a very lucrative strategy. Over the last two decades, these seven stocks have…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Up 14% in a day! Is this embattled FTSE 250 company on the road to recovery?

The sudden price surge in a lesser-known FTSE 250 stock caught my attention today. I decided to find out what’s…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is this FTSE growth superstar set to soar even higher on new drug results?

New drugs should significantly boost this FTSE stock’s earnings in my view. But even without them it looked very undervalued…

Read more »